id	sid	tid	token	lemma	pos
dpc-1664	1	1	dermatology	dermatology	NOUN
dpc-1664	1	2	:	:	PUNCT
dpc-1664	1	3	practical	practical	ADJ
dpc-1664	1	4	and	and	CCONJ
dpc-1664	1	5	conceptual	conceptual	ADJ
dpc-1664	1	6	dermatology	dermatology	NOUN
dpc-1664	1	7	practical	practical	ADJ
dpc-1664	1	8	&	&	CCONJ
dpc-1664	1	9	conceptual	conceptual	ADJ
dpc-1664	1	10	letter	letter	NOUN
dpc-1664	2	1	|	|	ADV
dpc-1664	2	2	dermatol	dermatol	ADJ
dpc-1664	2	3	pract	pract	NOUN
dpc-1664	2	4	concept	concept	NOUN
dpc-1664	2	5	.	.	PUNCT
dpc-1664	3	1	2021;11(4):e2021100	2021;11(4):e2021100	NUM
dpc-1664	3	2	1	1	NUM
dpc-1664	3	3	risankizumab	risankizumab	NOUN
dpc-1664	3	4	for	for	ADP
dpc-1664	3	5	plaque	plaque	NOUN
dpc-1664	3	6	and	and	CCONJ
dpc-1664	3	7	guttate	guttate	ADJ
dpc-1664	3	8	psoriasis	psoriasis	NOUN
dpc-1664	3	9	in	in	ADP
dpc-1664	3	10	a	a	DET
dpc-1664	3	11	patient	patient	NOUN
dpc-1664	3	12	with	with	ADP
dpc-1664	3	13	iga	iga	PROPN
dpc-1664	3	14	-	-	PUNCT
dpc-1664	3	15	related	relate	VERB
dpc-1664	3	16	glomerulonephritis	glomerulonephritis	NOUN
dpc-1664	3	17	annunziata	annunziata	VERB
dpc-1664	3	18	dattola1	dattola1	PROPN
dpc-1664	3	19	,	,	PUNCT
dpc-1664	3	20	arianna	arianna	PROPN
dpc-1664	3	21	zangrilli1	zangrilli1	PROPN
dpc-1664	3	22	,	,	PUNCT
dpc-1664	3	23	luca	luca	PROPN
dpc-1664	3	24	bianchi1	bianchi1	PROPN
dpc-1664	3	25	1	1	NUM
dpc-1664	3	26	department	department	NOUN
dpc-1664	3	27	of	of	ADP
dpc-1664	3	28	dermatology	dermatology	NOUN
dpc-1664	3	29	university	university	PROPN
dpc-1664	3	30	of	of	ADP
dpc-1664	3	31	rome	rome	PROPN
dpc-1664	3	32	“	"	PUNCT
dpc-1664	3	33	tor	tor	PROPN
dpc-1664	3	34	vergata	vergata	NOUN
dpc-1664	3	35	”	"	PUNCT
dpc-1664	3	36	,	,	PUNCT
dpc-1664	3	37	rome	rome	PROPN
dpc-1664	3	38	,	,	PUNCT
dpc-1664	3	39	italy	italy	PROPN
dpc-1664	3	40	key	key	ADJ
dpc-1664	3	41	words	word	NOUN
dpc-1664	3	42	:	:	PUNCT
dpc-1664	3	43	guttate	guttate	NOUN
dpc-1664	3	44	psoriasis	psoriasis	NOUN
dpc-1664	3	45	,	,	PUNCT
dpc-1664	3	46	risankizumab	risankizumab	NOUN
dpc-1664	3	47	,	,	PUNCT
dpc-1664	3	48	multi	multi	ADJ
dpc-1664	3	49	-	-	NOUN
dpc-1664	3	50	failure	failure	ADJ
dpc-1664	3	51	,	,	PUNCT
dpc-1664	3	52	renal	renal	ADJ
dpc-1664	3	53	disease	disease	NOUN
dpc-1664	3	54	citation	citation	NOUN
dpc-1664	3	55	:	:	PUNCT
dpc-1664	3	56	dattola	dattola	PROPN
dpc-1664	3	57	a	a	PRON
dpc-1664	3	58	,	,	PUNCT
dpc-1664	3	59	zangrilli	zangrilli	PROPN
dpc-1664	3	60	a	a	X
dpc-1664	3	61	,	,	PUNCT
dpc-1664	3	62	bianchi	bianchi	PROPN
dpc-1664	3	63	l.	l.	PROPN
dpc-1664	3	64	risankizumab	risankizumab	PROPN
dpc-1664	3	65	for	for	ADP
dpc-1664	3	66	plaque	plaque	NOUN
dpc-1664	3	67	and	and	CCONJ
dpc-1664	3	68	guttate	guttate	ADJ
dpc-1664	3	69	psoriasis	psoriasis	NOUN
dpc-1664	3	70	in	in	ADP
dpc-1664	3	71	a	a	DET
dpc-1664	3	72	patient	patient	NOUN
dpc-1664	3	73	with	with	ADP
dpc-1664	3	74	iga	iga	PROPN
dpc-1664	3	75	-related	-related	PROPN
dpc-1664	3	76	glomerulonephritis	glomerulonephritis	PROPN
dpc-1664	3	77	.	.	PUNCT
dpc-1664	4	1	dermatol	dermatol	NOUN
dpc-1664	4	2	pract	pract	PROPN
dpc-1664	4	3	concept	concept	NOUN
dpc-1664	4	4	.	.	PUNCT
dpc-1664	5	1	2021;11(4):e2021100	2021;11(4):e2021100	X
dpc-1664	5	2	.	.	X
dpc-1664	6	1	doi	doi	PROPN
dpc-1664	6	2	:	:	PUNCT
dpc-1664	6	3	https://doi.org/10.5826/dpc.1104a100	https://doi.org/10.5826/dpc.1104a100	PROPN
dpc-1664	6	4	accepted	accept	VERB
dpc-1664	6	5	:	:	PUNCT
dpc-1664	6	6	march	march	PROPN
dpc-1664	6	7	8	8	NUM
dpc-1664	6	8	,	,	PUNCT
dpc-1664	6	9	2021	2021	NUM
dpc-1664	6	10	;	;	PUNCT
dpc-1664	6	11	published	publish	VERB
dpc-1664	6	12	:	:	PUNCT
dpc-1664	6	13	october	october	PROPN
dpc-1664	6	14	,	,	PUNCT
dpc-1664	6	15	2021	2021	NUM
dpc-1664	6	16	copyright	copyright	NOUN
dpc-1664	6	17	:	:	PUNCT
dpc-1664	6	18	©	©	PROPN
dpc-1664	6	19	2021	2021	NUM
dpc-1664	6	20	dattola	dattola	PROPN
dpc-1664	6	21	et	et	PROPN
dpc-1664	6	22	al	al	PROPN
dpc-1664	6	23	.	.	PUNCT
dpc-1664	7	1	this	this	PRON
dpc-1664	7	2	is	be	AUX
dpc-1664	7	3	an	an	DET
dpc-1664	7	4	open	open	ADJ
dpc-1664	7	5	-	-	PUNCT
dpc-1664	7	6	access	access	NOUN
dpc-1664	7	7	article	article	NOUN
dpc-1664	7	8	distributed	distribute	VERB
dpc-1664	7	9	under	under	ADP
dpc-1664	7	10	the	the	DET
dpc-1664	7	11	terms	term	NOUN
dpc-1664	7	12	of	of	ADP
dpc-1664	7	13	the	the	DET
dpc-1664	7	14	creative	creative	ADJ
dpc-1664	7	15	commons	common	NOUN
dpc-1664	7	16	attribution	attribution	NOUN
dpc-1664	7	17	license	license	NOUN
dpc-1664	7	18	by	by	ADP
dpc-1664	7	19	-	-	PUNCT
dpc-1664	7	20	nc-4.0	nc-4.0	NOUN
dpc-1664	7	21	,	,	PUNCT
dpc-1664	7	22	which	which	PRON
dpc-1664	7	23	permits	permit	VERB
dpc-1664	7	24	unrestricted	unrestricted	ADJ
dpc-1664	7	25	noncommercial	noncommercial	ADJ
dpc-1664	7	26	use	use	NOUN
dpc-1664	7	27	,	,	PUNCT
dpc-1664	7	28	distribution	distribution	NOUN
dpc-1664	7	29	,	,	PUNCT
dpc-1664	7	30	and	and	CCONJ
dpc-1664	7	31	reproduction	reproduction	NOUN
dpc-1664	7	32	in	in	ADP
dpc-1664	7	33	any	any	DET
dpc-1664	7	34	medium	medium	NOUN
dpc-1664	7	35	,	,	PUNCT
dpc-1664	7	36	provided	provide	VERB
dpc-1664	7	37	the	the	DET
dpc-1664	7	38	original	original	ADJ
dpc-1664	7	39	authors	author	NOUN
dpc-1664	7	40	and	and	CCONJ
dpc-1664	7	41	source	source	NOUN
dpc-1664	7	42	are	be	AUX
dpc-1664	7	43	credited	credit	VERB
dpc-1664	7	44	.	.	PUNCT
dpc-1664	8	1	funding	funding	NOUN
dpc-1664	8	2	:	:	PUNCT
dpc-1664	8	3	none	none	NOUN
dpc-1664	8	4	.	.	PUNCT
dpc-1664	9	1	competing	compete	VERB
dpc-1664	9	2	interests	interest	NOUN
dpc-1664	9	3	:	:	PUNCT
dpc-1664	9	4	none	none	NOUN
dpc-1664	9	5	.	.	PUNCT
dpc-1664	10	1	authorship	authorship	NOUN
dpc-1664	10	2	:	:	PUNCT
dpc-1664	10	3	all	all	DET
dpc-1664	10	4	authors	author	NOUN
dpc-1664	10	5	have	have	AUX
dpc-1664	10	6	contributed	contribute	VERB
dpc-1664	10	7	significantly	significantly	ADV
dpc-1664	10	8	to	to	ADP
dpc-1664	10	9	this	this	DET
dpc-1664	10	10	publication	publication	NOUN
dpc-1664	10	11	.	.	PUNCT
dpc-1664	11	1	corresponding	correspond	VERB
dpc-1664	11	2	author	author	NOUN
dpc-1664	11	3	:	:	PUNCT
dpc-1664	11	4	annunziata	annunziata	PROPN
dpc-1664	11	5	dattola	dattola	PROPN
dpc-1664	11	6	,	,	PUNCT
dpc-1664	11	7	department	department	NOUN
dpc-1664	11	8	of	of	ADP
dpc-1664	11	9	dermatology	dermatology	NOUN
dpc-1664	11	10	,	,	PUNCT
dpc-1664	11	11	policlinico	policlinico	NOUN
dpc-1664	11	12	tor	tor	NOUN
dpc-1664	11	13	vergata	vergata	PROPN
dpc-1664	11	14	,	,	PUNCT
dpc-1664	11	15	rome	rome	PROPN
dpc-1664	11	16	,	,	PUNCT
dpc-1664	11	17	italy	italy	PROPN
dpc-1664	11	18	.	.	PUNCT
dpc-1664	12	1	email	email	NOUN
dpc-1664	12	2	:	:	PUNCT
dpc-1664	13	1	nancydattola@gmail.com	nancydattola@gmail.com	X
dpc-1664	13	2	introduction	introduction	NOUN
dpc-1664	13	3	guttate	guttate	NOUN
dpc-1664	13	4	psoriasis	psoriasis	NOUN
dpc-1664	13	5	is	be	AUX
dpc-1664	13	6	a	a	DET
dpc-1664	13	7	subtype	subtype	NOUN
dpc-1664	13	8	of	of	ADP
dpc-1664	13	9	psoriasis	psoriasis	NOUN
dpc-1664	13	10	characterized	characterize	VERB
dpc-1664	13	11	by	by	ADP
dpc-1664	13	12	acute	acute	ADJ
dpc-1664	13	13	eruption	eruption	NOUN
dpc-1664	13	14	of	of	ADP
dpc-1664	13	15	numerous	numerous	ADJ
dpc-1664	13	16	small	small	ADJ
dpc-1664	13	17	,	,	PUNCT
dpc-1664	13	18	erythematous	erythematous	ADJ
dpc-1664	13	19	papules	papule	NOUN
dpc-1664	13	20	and	and	CCONJ
dpc-1664	13	21	plaques	plaque	NOUN
dpc-1664	13	22	.	.	PUNCT
dpc-1664	14	1	it	it	PRON
dpc-1664	14	2	usually	usually	ADV
dpc-1664	14	3	occurs	occur	VERB
dpc-1664	14	4	in	in	ADP
dpc-1664	14	5	children	child	NOUN
dpc-1664	14	6	and	and	CCONJ
dpc-1664	14	7	adolescents	adolescent	NOUN
dpc-1664	14	8	,	,	PUNCT
dpc-1664	14	9	but	but	CCONJ
dpc-1664	14	10	it	it	PRON
dpc-1664	14	11	can	can	AUX
dpc-1664	14	12	occur	occur	VERB
dpc-1664	14	13	in	in	ADP
dpc-1664	14	14	other	other	ADJ
dpc-1664	14	15	age	age	NOUN
dpc-1664	14	16	groups	group	NOUN
dpc-1664	14	17	.	.	PUNCT
dpc-1664	15	1	streptococcus	streptococcus	NOUN
dpc-1664	15	2	infection	infection	NOUN
dpc-1664	15	3	is	be	AUX
dpc-1664	15	4	an	an	DET
dpc-1664	15	5	important	important	ADJ
dpc-1664	15	6	risk	risk	NOUN
dpc-1664	15	7	factor	factor	NOUN
dpc-1664	15	8	which	which	PRON
dpc-1664	15	9	can	can	AUX
dpc-1664	15	10	usually	usually	ADV
dpc-1664	15	11	precede	precede	VERB
dpc-1664	15	12	its	its	PRON
dpc-1664	15	13	development	development	NOUN
dpc-1664	15	14	by	by	ADP
dpc-1664	15	15	2	2	NUM
dpc-1664	15	16	-	-	SYM
dpc-1664	15	17	3	3	NUM
dpc-1664	15	18	weeks	week	NOUN
dpc-1664	15	19	[	[	X
dpc-1664	15	20	1	1	NUM
dpc-1664	15	21	]	]	PUNCT
dpc-1664	15	22	.	.	PUNCT
dpc-1664	16	1	risankizumab	risankizumab	PROPN
dpc-1664	16	2	is	be	AUX
dpc-1664	16	3	a	a	DET
dpc-1664	16	4	novel	novel	ADJ
dpc-1664	16	5	anti	anti	ADJ
dpc-1664	16	6	-	-	ADJ
dpc-1664	16	7	interleukin	interleukin	ADJ
dpc-1664	16	8	23	23	NUM
dpc-1664	16	9	humanized	humanize	VERB
dpc-1664	16	10	antibody	antibody	NOUN
dpc-1664	16	11	developed	develop	VERB
dpc-1664	16	12	for	for	ADP
dpc-1664	16	13	severe	severe	ADJ
dpc-1664	16	14	plaque	plaque	NOUN
dpc-1664	16	15	psoriasis	psoriasis	NOUN
dpc-1664	16	16	.	.	PUNCT
dpc-1664	17	1	it	it	PRON
dpc-1664	17	2	is	be	AUX
dpc-1664	17	3	a	a	DET
dpc-1664	17	4	humanized	humanize	VERB
dpc-1664	17	5	immunoglobulin	immunoglobulin	NOUN
dpc-1664	17	6	monoclonal	monoclonal	NOUN
dpc-1664	17	7	antibody	antibody	NOUN
dpc-1664	17	8	(	(	PUNCT
dpc-1664	17	9	ig	ig	NOUN
dpc-1664	17	10	)	)	PUNCT
dpc-1664	17	11	g1	g1	NOUN
dpc-1664	17	12	selectively	selectively	ADV
dpc-1664	17	13	binding	bind	VERB
dpc-1664	17	14	to	to	ADP
dpc-1664	17	15	and	and	CCONJ
dpc-1664	17	16	inhibiting	inhibit	VERB
dpc-1664	17	17	p19	p19	NOUN
dpc-1664	17	18	subunit	subunit	NOUN
dpc-1664	17	19	of	of	ADP
dpc-1664	17	20	il-23	il-23	NOUN
dpc-1664	17	21	.	.	PUNCT
dpc-1664	18	1	no	no	DET
dpc-1664	18	2	clinical	clinical	ADJ
dpc-1664	18	3	cases	case	NOUN
dpc-1664	18	4	are	be	AUX
dpc-1664	18	5	reported	report	VERB
dpc-1664	18	6	in	in	ADP
dpc-1664	18	7	literature	literature	NOUN
dpc-1664	18	8	regarding	regard	VERB
dpc-1664	18	9	the	the	DET
dpc-1664	18	10	use	use	NOUN
dpc-1664	18	11	of	of	ADP
dpc-1664	18	12	risankizumab	risankizumab	NOUN
dpc-1664	18	13	for	for	ADP
dpc-1664	18	14	guttate	guttate	ADJ
dpc-1664	18	15	psoriasis	psoriasis	NOUN
dpc-1664	18	16	’	'	PUNCT
dpc-1664	18	17	treatment	treatment	NOUN
dpc-1664	18	18	,	,	PUNCT
dpc-1664	18	19	but	but	CCONJ
dpc-1664	18	20	there	there	PRON
dpc-1664	18	21	is	be	VERB
dpc-1664	18	22	evidence	evidence	NOUN
dpc-1664	18	23	reporting	report	VERB
dpc-1664	18	24	resolution	resolution	NOUN
dpc-1664	18	25	of	of	ADP
dpc-1664	18	26	guttate	guttate	ADJ
dpc-1664	18	27	psoriasis	psoriasis	NOUN
dpc-1664	18	28	after	after	ADP
dpc-1664	18	29	1	1	NUM
dpc-1664	18	30	guselkumab	guselkumab	NOUN
dpc-1664	18	31	injection	injection	NOUN
dpc-1664	18	32	,	,	PUNCT
dpc-1664	18	33	another	another	DET
dpc-1664	18	34	novel	novel	ADJ
dpc-1664	18	35	anti	anti	NOUN
dpc-1664	18	36	-	-	NOUN
dpc-1664	18	37	il-23	il-23	NOUN
dpc-1664	18	38	[	[	X
dpc-1664	18	39	2	2	NUM
dpc-1664	18	40	]	]	PUNCT
dpc-1664	18	41	.	.	PUNCT
dpc-1664	19	1	phase	phase	NOUN
dpc-1664	19	2	3	3	NUM
dpc-1664	19	3	trials	trial	NOUN
dpc-1664	19	4	evaluating	evaluate	VERB
dpc-1664	19	5	the	the	DET
dpc-1664	19	6	effectiveness	effectiveness	NOUN
dpc-1664	19	7	and	and	CCONJ
dpc-1664	19	8	safety	safety	NOUN
dpc-1664	19	9	of	of	ADP
dpc-1664	19	10	risankizumab	risankizumab	NOUN
dpc-1664	19	11	in	in	ADP
dpc-1664	19	12	patients	patient	NOUN
dpc-1664	19	13	with	with	ADP
dpc-1664	19	14	moderate	moderate	ADJ
dpc-1664	19	15	-	-	PUNCT
dpc-1664	19	16	to	to	ADP
dpc-1664	19	17	-	-	PUNCT
dpc-1664	19	18	severe	severe	ADJ
dpc-1664	19	19	plaque	plaque	NOUN
dpc-1664	19	20	psoriasis	psoriasis	NOUN
dpc-1664	19	21	were	be	AUX
dpc-1664	19	22	:	:	PUNCT
dpc-1664	19	23	ultimma-1	ultimma-1	NUM
dpc-1664	19	24	(	(	PUNCT
dpc-1664	19	25	n	n	NOUN
dpc-1664	19	26	=	=	NUM
dpc-1664	19	27	506	506	NUM
dpc-1664	19	28	)	)	PUNCT
dpc-1664	19	29	,	,	PUNCT
dpc-1664	19	30	ultimma-2	ultimma-2	PROPN
dpc-1664	19	31	(	(	PUNCT
dpc-1664	19	32	n	n	NOUN
dpc-1664	19	33	=	=	NUM
dpc-1664	19	34	491	491	NUM
dpc-1664	19	35	)	)	PUNCT
dpc-1664	19	36	,	,	PUNCT
dpc-1664	19	37	immhance	immhance	NOUN
dpc-1664	19	38	(	(	PUNCT
dpc-1664	19	39	n	n	NOUN
dpc-1664	19	40	=	=	SYM
dpc-1664	19	41	507	507	NUM
dpc-1664	19	42	)	)	PUNCT
dpc-1664	19	43	,	,	PUNCT
dpc-1664	19	44	and	and	CCONJ
dpc-1664	19	45	immvent	immvent	NOUN
dpc-1664	19	46	(	(	PUNCT
dpc-1664	19	47	n	n	NOUN
dpc-1664	19	48	=	=	SYM
dpc-1664	19	49	605	605	NUM
dpc-1664	19	50	)	)	PUNCT
dpc-1664	19	51	.	.	PUNCT
dpc-1664	20	1	in	in	ADP
dpc-1664	20	2	ultimma-1	ultimma-1	NUM
dpc-1664	20	3	and	and	CCONJ
dpc-1664	20	4	ultimma-2	ultimma-2	NUM
dpc-1664	20	5	,	,	PUNCT
dpc-1664	20	6	randomized	randomize	VERB
dpc-1664	20	7	,	,	PUNCT
dpc-1664	20	8	double	double	ADJ
dpc-1664	20	9	-	-	PUNCT
dpc-1664	20	10	blind	blind	ADJ
dpc-1664	20	11	,	,	PUNCT
dpc-1664	20	12	placebocontrolled	placebocontrolle	VERB
dpc-1664	20	13	,	,	PUNCT
dpc-1664	20	14	and	and	CCONJ
dpc-1664	20	15	active	active	ADJ
dpc-1664	20	16	comparator	comparator	NOUN
dpc-1664	20	17	-	-	PUNCT
dpc-1664	20	18	controlled	control	VERB
dpc-1664	20	19	trials	trial	NOUN
dpc-1664	20	20	,	,	PUNCT
dpc-1664	20	21	patients	patient	NOUN
dpc-1664	20	22	were	be	AUX
dpc-1664	20	23	randomized	randomize	VERB
dpc-1664	20	24	for	for	ADP
dpc-1664	20	25	risankizumab	risankizumab	NOUN
dpc-1664	20	26	150	150	NUM
dpc-1664	20	27	mg	mg	PROPN
dpc-1664	20	28	,	,	PUNCT
dpc-1664	20	29	ustekinumab	ustekinumab	NOUN
dpc-1664	20	30	(	(	PUNCT
dpc-1664	20	31	45	45	NUM
dpc-1664	20	32	mg	mg	NOUN
dpc-1664	20	33	or	or	CCONJ
dpc-1664	20	34	90	90	NUM
dpc-1664	20	35	mg	mg	NUM
dpc-1664	20	36	)	)	PUNCT
dpc-1664	20	37	,	,	PUNCT
dpc-1664	20	38	or	or	CCONJ
dpc-1664	20	39	placebo	placebo	NOUN
dpc-1664	20	40	.	.	PUNCT
dpc-1664	21	1	results	result	NOUN
dpc-1664	21	2	showed	show	VERB
dpc-1664	21	3	a	a	DET
dpc-1664	21	4	higher	high	ADJ
dpc-1664	21	5	efficacy	efficacy	NOUN
dpc-1664	21	6	of	of	ADP
dpc-1664	21	7	risankizumab	risankizumab	NOUN
dpc-1664	21	8	compared	compare	VERB
dpc-1664	21	9	to	to	ADP
dpc-1664	21	10	ustekinumab	ustekinumab	NOUN
dpc-1664	21	11	and	and	CCONJ
dpc-1664	21	12	placebo	placebo	NOUN
dpc-1664	21	13	;	;	PUNCT
dpc-1664	21	14	at	at	ADP
dpc-1664	21	15	week	week	NOUN
dpc-1664	21	16	16	16	NUM
dpc-1664	21	17	,	,	PUNCT
dpc-1664	21	18	psoriasis	psoriasis	NOUN
dpc-1664	21	19	area	area	NOUN
dpc-1664	21	20	and	and	CCONJ
dpc-1664	21	21	severity	severity	NOUN
dpc-1664	21	22	index	index	NOUN
dpc-1664	21	23	90	90	NUM
dpc-1664	21	24	(	(	PUNCT
dpc-1664	21	25	pasi	pasi	NOUN
dpc-1664	21	26	90	90	NUM
dpc-1664	21	27	)	)	PUNCT
dpc-1664	21	28	was	be	AUX
dpc-1664	21	29	achieved	achieve	VERB
dpc-1664	21	30	by	by	ADP
dpc-1664	21	31	75.3	75.3	NUM
dpc-1664	21	32	%	%	NOUN
dpc-1664	21	33	and	and	CCONJ
dpc-1664	21	34	74.8	74.8	NUM
dpc-1664	21	35	%	%	NOUN
dpc-1664	21	36	of	of	ADP
dpc-1664	21	37	patients	patient	NOUN
dpc-1664	21	38	receiving	receive	VERB
dpc-1664	21	39	risankizumab	risankizumab	NOUN
dpc-1664	21	40	versus	versus	ADP
dpc-1664	21	41	42.0	42.0	NUM
dpc-1664	21	42	%	%	NOUN
dpc-1664	21	43	and	and	CCONJ
dpc-1664	21	44	47.5	47.5	NUM
dpc-1664	21	45	%	%	NOUN
dpc-1664	21	46	receiving	receive	VERB
dpc-1664	21	47	ustekinumab	ustekinumab	NOUN
dpc-1664	21	48	,	,	PUNCT
dpc-1664	21	49	respectively	respectively	ADV
dpc-1664	21	50	in	in	ADP
dpc-1664	21	51	ultimma-1	ultimma-1	NUM
dpc-1664	21	52	and	and	CCONJ
dpc-1664	21	53	ultimma-2	ultimma-2	PROPN
dpc-1664	22	1	[	[	X
dpc-1664	22	2	3	3	NUM
dpc-1664	22	3	]	]	PUNCT
dpc-1664	22	4	.	.	PUNCT
dpc-1664	23	1	case	case	NOUN
dpc-1664	23	2	presentation	presentation	NOUN
dpc-1664	23	3	we	we	PRON
dpc-1664	23	4	describe	describe	VERB
dpc-1664	23	5	a	a	DET
dpc-1664	23	6	case	case	NOUN
dpc-1664	23	7	of	of	ADP
dpc-1664	23	8	a	a	DET
dpc-1664	23	9	32	32	NUM
dpc-1664	23	10	-	-	PUNCT
dpc-1664	23	11	year	year	NOUN
dpc-1664	23	12	-	-	PUNCT
dpc-1664	23	13	old	old	ADJ
dpc-1664	23	14	female	female	ADJ
dpc-1664	23	15	patient	patient	NOUN
dpc-1664	23	16	affected	affect	VERB
dpc-1664	23	17	by	by	ADP
dpc-1664	23	18	plaque	plaque	NOUN
dpc-1664	23	19	psoriasis	psoriasis	NOUN
dpc-1664	23	20	at	at	ADP
dpc-1664	23	21	the	the	DET
dpc-1664	23	22	level	level	NOUN
dpc-1664	23	23	of	of	ADP
dpc-1664	23	24	the	the	DET
dpc-1664	23	25	trunk	trunk	NOUN
dpc-1664	23	26	and	and	CCONJ
dpc-1664	23	27	the	the	DET
dpc-1664	23	28	extremities	extremity	NOUN
dpc-1664	23	29	,	,	PUNCT
dpc-1664	23	30	covering	cover	VERB
dpc-1664	23	31	approximately	approximately	ADV
dpc-1664	23	32	30	30	NUM
dpc-1664	23	33	%	%	NOUN
dpc-1664	23	34	of	of	ADP
dpc-1664	23	35	the	the	DET
dpc-1664	23	36	patient	patient	NOUN
dpc-1664	23	37	’s	’s	PART
dpc-1664	23	38	body	body	NOUN
dpc-1664	23	39	surface	surface	NOUN
dpc-1664	23	40	area	area	NOUN
dpc-1664	23	41	(	(	PUNCT
dpc-1664	23	42	pasi	pasi	NOUN
dpc-1664	23	43	score	score	NOUN
dpc-1664	23	44	18	18	NUM
dpc-1664	23	45	)	)	PUNCT
dpc-1664	23	46	.	.	PUNCT
dpc-1664	24	1	she	she	PRON
dpc-1664	24	2	is	be	AUX
dpc-1664	24	3	also	also	ADV
dpc-1664	24	4	affected	affect	VERB
dpc-1664	24	5	by	by	ADP
dpc-1664	24	6	“	"	PUNCT
dpc-1664	24	7	early	early	ADJ
dpc-1664	24	8	stages	stage	NOUN
dpc-1664	24	9	”	"	PUNCT
dpc-1664	24	10	of	of	ADP
dpc-1664	24	11	glomerulonephritis	glomerulonephritis	PROPN
dpc-1664	24	12	iga	iga	PROPN
dpc-1664	24	13	-	-	PUNCT
dpc-1664	24	14	related	relate	VERB
dpc-1664	24	15	for	for	ADP
dpc-1664	24	16	10	10	NUM
dpc-1664	24	17	years	year	NOUN
dpc-1664	24	18	,	,	PUNCT
dpc-1664	24	19	now	now	ADV
dpc-1664	24	20	under	under	ADP
dpc-1664	24	21	control	control	NOUN
dpc-1664	24	22	without	without	ADP
dpc-1664	24	23	treatment	treatment	NOUN
dpc-1664	24	24	.	.	PUNCT
dpc-1664	25	1	the	the	DET
dpc-1664	25	2	patient	patient	NOUN
dpc-1664	25	3	was	be	AUX
dpc-1664	25	4	treated	treat	VERB
dpc-1664	25	5	with	with	ADP
dpc-1664	25	6	several	several	ADJ
dpc-1664	25	7	topical	topical	ADJ
dpc-1664	25	8	treatments	treatment	NOUN
dpc-1664	25	9	,	,	PUNCT
dpc-1664	25	10	phototherapy	phototherapy	NOUN
dpc-1664	25	11	,	,	PUNCT
dpc-1664	25	12	systemic	systemic	ADJ
dpc-1664	25	13	corticosteroids	corticosteroid	NOUN
dpc-1664	25	14	,	,	PUNCT
dpc-1664	25	15	and	and	CCONJ
dpc-1664	25	16	methotrexate	methotrexate	VERB
dpc-1664	25	17	for	for	ADP
dpc-1664	25	18	6	6	NUM
dpc-1664	25	19	months	month	NOUN
dpc-1664	25	20	with	with	ADP
dpc-1664	25	21	no	no	DET
dpc-1664	25	22	clinical	clinical	ADJ
dpc-1664	25	23	efficacy	efficacy	NOUN
dpc-1664	25	24	.	.	PUNCT
dpc-1664	26	1	cyclosporine	cyclosporine	PROPN
dpc-1664	26	2	was	be	AUX
dpc-1664	26	3	administered	administer	VERB
dpc-1664	26	4	for	for	ADP
dpc-1664	26	5	glomerulonephritis	glomerulonephritis	NOUN
dpc-1664	26	6	.	.	PUNCT
dpc-1664	27	1	in	in	ADP
dpc-1664	27	2	2016	2016	NUM
dpc-1664	27	3	,	,	PUNCT
dpc-1664	27	4	after	after	ADP
dpc-1664	27	5	screening	screen	VERB
dpc-1664	27	6	for	for	ADP
dpc-1664	27	7	2	2	NUM
dpc-1664	27	8	letter	letter	NOUN
dpc-1664	27	9	|	|	ADV
dpc-1664	27	10	dermatol	dermatol	ADJ
dpc-1664	27	11	pract	pract	NOUN
dpc-1664	27	12	concept	concept	NOUN
dpc-1664	27	13	.	.	PUNCT
dpc-1664	28	1	2021;11(4):e2021100	2021;11(4):e2021100	NUM
dpc-1664	28	2	biological	biological	ADJ
dpc-1664	28	3	treatment	treatment	NOUN
dpc-1664	28	4	,	,	PUNCT
dpc-1664	28	5	she	she	PRON
dpc-1664	28	6	started	start	VERB
dpc-1664	28	7	treatment	treatment	NOUN
dpc-1664	28	8	with	with	ADP
dpc-1664	28	9	etanercept	etanercept	NOUN
dpc-1664	28	10	50	50	NUM
dpc-1664	28	11	mg	mg	NOUN
dpc-1664	28	12	subcutaneous	subcutaneous	ADJ
dpc-1664	28	13	injection	injection	NOUN
dpc-1664	28	14	every	every	DET
dpc-1664	28	15	week	week	NOUN
dpc-1664	28	16	.	.	PUNCT
dpc-1664	29	1	after	after	ADP
dpc-1664	29	2	24	24	NUM
dpc-1664	29	3	weeks	week	NOUN
dpc-1664	29	4	of	of	ADP
dpc-1664	29	5	treatment	treatment	NOUN
dpc-1664	29	6	,	,	PUNCT
dpc-1664	29	7	following	follow	VERB
dpc-1664	29	8	the	the	DET
dpc-1664	29	9	loss	loss	NOUN
dpc-1664	29	10	of	of	ADP
dpc-1664	29	11	efficacy	efficacy	NOUN
dpc-1664	29	12	with	with	ADP
dpc-1664	29	13	etanercept	etanercept	NOUN
dpc-1664	29	14	,	,	PUNCT
dpc-1664	29	15	we	we	PRON
dpc-1664	29	16	began	begin	VERB
dpc-1664	29	17	adalimumab	adalimumab	NOUN
dpc-1664	29	18	40	40	NUM
dpc-1664	29	19	mg	mg	NOUN
dpc-1664	29	20	subcutaneous	subcutaneous	ADJ
dpc-1664	29	21	injection	injection	NOUN
dpc-1664	29	22	therapy	therapy	NOUN
dpc-1664	29	23	.	.	PUNCT
dpc-1664	30	1	while	while	SCONJ
dpc-1664	30	2	the	the	DET
dpc-1664	30	3	patient	patient	NOUN
dpc-1664	30	4	was	be	AUX
dpc-1664	30	5	undergoing	undergo	VERB
dpc-1664	30	6	adalimumab	adalimumab	NOUN
dpc-1664	30	7	treatment	treatment	NOUN
dpc-1664	30	8	,	,	PUNCT
dpc-1664	30	9	we	we	PRON
dpc-1664	30	10	observed	observe	VERB
dpc-1664	30	11	a	a	DET
dpc-1664	30	12	good	good	ADJ
dpc-1664	30	13	control	control	NOUN
dpc-1664	30	14	of	of	ADP
dpc-1664	30	15	cutaneous	cutaneous	ADJ
dpc-1664	30	16	psoriasis	psoriasis	NOUN
dpc-1664	30	17	(	(	PUNCT
dpc-1664	30	18	pasi	pasi	VERB
dpc-1664	30	19	residual	residual	ADJ
dpc-1664	30	20	3	3	NUM
dpc-1664	30	21	)	)	PUNCT
dpc-1664	30	22	for	for	ADP
dpc-1664	30	23	12	12	NUM
dpc-1664	30	24	months	month	NOUN
dpc-1664	30	25	.	.	PUNCT
dpc-1664	31	1	after	after	ADP
dpc-1664	31	2	12	12	NUM
dpc-1664	31	3	months	month	NOUN
dpc-1664	31	4	with	with	ADP
dpc-1664	31	5	adalimumab	adalimumab	NOUN
dpc-1664	31	6	the	the	DET
dpc-1664	31	7	patient	patient	NOUN
dpc-1664	31	8	developed	develop	VERB
dpc-1664	31	9	psoriatic	psoriatic	ADJ
dpc-1664	31	10	lesions	lesion	NOUN
dpc-1664	31	11	at	at	ADP
dpc-1664	31	12	the	the	DET
dpc-1664	31	13	limbs	limb	NOUN
dpc-1664	31	14	and	and	CCONJ
dpc-1664	31	15	trunk	trunk	NOUN
dpc-1664	31	16	;	;	PUNCT
dpc-1664	31	17	we	we	PRON
dpc-1664	31	18	decided	decide	VERB
dpc-1664	31	19	to	to	PART
dpc-1664	31	20	continue	continue	VERB
dpc-1664	31	21	the	the	DET
dpc-1664	31	22	treatment	treatment	NOUN
dpc-1664	31	23	evaluating	evaluate	VERB
dpc-1664	31	24	the	the	DET
dpc-1664	31	25	patient	patient	NOUN
dpc-1664	31	26	at	at	ADP
dpc-1664	31	27	the	the	DET
dpc-1664	31	28	next	next	ADJ
dpc-1664	31	29	visit	visit	NOUN
dpc-1664	31	30	.	.	PUNCT
dpc-1664	32	1	at	at	ADP
dpc-1664	32	2	follow	follow	NOUN
dpc-1664	32	3	-	-	PUNCT
dpc-1664	32	4	up	up	NOUN
dpc-1664	32	5	we	we	PRON
dpc-1664	32	6	noticed	notice	VERB
dpc-1664	32	7	an	an	DET
dpc-1664	32	8	important	important	ADJ
dpc-1664	32	9	flair	flair	NOUN
dpc-1664	32	10	of	of	ADP
dpc-1664	32	11	the	the	DET
dpc-1664	32	12	skin	skin	NOUN
dpc-1664	32	13	lesions	lesion	NOUN
dpc-1664	32	14	,	,	PUNCT
dpc-1664	32	15	psoriatic	psoriatic	ADJ
dpc-1664	32	16	plaques	plaque	NOUN
dpc-1664	32	17	on	on	ADP
dpc-1664	32	18	the	the	DET
dpc-1664	32	19	arms	arm	NOUN
dpc-1664	32	20	,	,	PUNCT
dpc-1664	32	21	and	and	CCONJ
dpc-1664	32	22	guttate	guttate	VERB
dpc-1664	32	23	psoriasis	psoriasis	NOUN
dpc-1664	32	24	on	on	ADP
dpc-1664	32	25	the	the	DET
dpc-1664	32	26	trunk	trunk	NOUN
dpc-1664	32	27	.	.	PUNCT
dpc-1664	33	1	adalimumab	adalimumab	NOUN
dpc-1664	33	2	treatment	treatment	NOUN
dpc-1664	33	3	was	be	AUX
dpc-1664	33	4	therefore	therefore	ADV
dpc-1664	33	5	discontinued	discontinue	VERB
dpc-1664	33	6	.	.	PUNCT
dpc-1664	34	1	laboratory	laboratory	NOUN
dpc-1664	34	2	test	test	NOUN
dpc-1664	34	3	did	do	AUX
dpc-1664	34	4	not	not	PART
dpc-1664	34	5	detect	detect	VERB
dpc-1664	34	6	abnormalities	abnormality	NOUN
dpc-1664	34	7	,	,	PUNCT
dpc-1664	34	8	streptozyme	streptozyme	NOUN
dpc-1664	34	9	test	test	NOUN
dpc-1664	34	10	was	be	AUX
dpc-1664	34	11	performed	perform	VERB
dpc-1664	34	12	because	because	SCONJ
dpc-1664	34	13	of	of	ADP
dpc-1664	34	14	the	the	DET
dpc-1664	34	15	appearance	appearance	NOUN
dpc-1664	34	16	of	of	ADP
dpc-1664	34	17	guttate	guttate	ADJ
dpc-1664	34	18	psoriasis	psoriasis	NOUN
dpc-1664	34	19	and	and	CCONJ
dpc-1664	34	20	result	result	NOUN
dpc-1664	34	21	was	be	AUX
dpc-1664	34	22	negative	negative	ADJ
dpc-1664	34	23	.	.	PUNCT
dpc-1664	35	1	treatment	treatment	NOUN
dpc-1664	35	2	with	with	ADP
dpc-1664	35	3	secukinumab	secukinumab	NOUN
dpc-1664	35	4	was	be	AUX
dpc-1664	35	5	excluded	exclude	VERB
dpc-1664	35	6	because	because	SCONJ
dpc-1664	35	7	of	of	ADP
dpc-1664	35	8	recurrent	recurrent	ADJ
dpc-1664	35	9	genital	genital	ADJ
dpc-1664	35	10	candidiasis	candidiasis	NOUN
dpc-1664	35	11	medical	medical	ADJ
dpc-1664	35	12	history	history	NOUN
dpc-1664	35	13	.	.	PUNCT
dpc-1664	36	1	ixekizumab	ixekizumab	NOUN
dpc-1664	36	2	was	be	AUX
dpc-1664	36	3	also	also	ADV
dpc-1664	36	4	excluded	exclude	VERB
dpc-1664	36	5	due	due	ADJ
dpc-1664	36	6	to	to	ADP
dpc-1664	36	7	eczematous	eczematous	ADJ
dpc-1664	36	8	episodes	episode	NOUN
dpc-1664	36	9	localized	localize	VERB
dpc-1664	36	10	on	on	ADP
dpc-1664	36	11	the	the	DET
dpc-1664	36	12	patient	patient	NOUN
dpc-1664	36	13	’s	’s	PART
dpc-1664	36	14	face	face	NOUN
dpc-1664	36	15	.	.	PUNCT
dpc-1664	37	1	in	in	ADP
dpc-1664	37	2	january	january	PROPN
dpc-1664	37	3	2019	2019	NUM
dpc-1664	37	4	risankizumab	risankizumab	NOUN
dpc-1664	37	5	therapy	therapy	NOUN
dpc-1664	37	6	was	be	AUX
dpc-1664	37	7	started	start	VERB
dpc-1664	37	8	(	(	PUNCT
dpc-1664	37	9	150	150	NUM
dpc-1664	37	10	 	 	SPACE
dpc-1664	37	11	mg	mg	ADJ
dpc-1664	37	12	subcutaneous	subcutaneous	ADJ
dpc-1664	37	13	injection	injection	NOUN
dpc-1664	37	14	)	)	PUNCT
dpc-1664	37	15	(	(	PUNCT
dpc-1664	37	16	figure	figure	NOUN
dpc-1664	37	17	1a	1a	NOUN
dpc-1664	37	18	)	)	PUNCT
dpc-1664	37	19	.	.	PUNCT
dpc-1664	38	1	after	after	ADP
dpc-1664	38	2	1	1	NUM
dpc-1664	38	3	month	month	NOUN
dpc-1664	38	4	of	of	ADP
dpc-1664	38	5	treatment	treatment	NOUN
dpc-1664	38	6	followed	follow	VERB
dpc-1664	38	7	by	by	ADP
dpc-1664	38	8	an	an	DET
dpc-1664	38	9	episode	episode	NOUN
dpc-1664	38	10	of	of	ADP
dpc-1664	38	11	sore	sore	ADJ
dpc-1664	38	12	throat	throat	NOUN
dpc-1664	38	13	with	with	ADP
dpc-1664	38	14	positive	positive	ADJ
dpc-1664	38	15	streptozyme	streptozyme	NOUN
dpc-1664	38	16	test	test	NOUN
dpc-1664	38	17	treated	treat	VERB
dpc-1664	38	18	only	only	ADV
dpc-1664	38	19	with	with	ADP
dpc-1664	38	20	streptococcus	streptococcus	NOUN
dpc-1664	38	21	salivarius	salivarius	NOUN
dpc-1664	38	22	probiotics	probiotic	NOUN
dpc-1664	38	23	,	,	PUNCT
dpc-1664	38	24	the	the	DET
dpc-1664	38	25	patient	patient	NOUN
dpc-1664	38	26	’s	’s	PART
dpc-1664	38	27	clinical	clinical	ADJ
dpc-1664	38	28	manifestations	manifestation	NOUN
dpc-1664	38	29	worsened	worsen	VERB
dpc-1664	38	30	,	,	PUNCT
dpc-1664	38	31	shifting	shift	VERB
dpc-1664	38	32	from	from	ADP
dpc-1664	38	33	a	a	DET
dpc-1664	38	34	pasi	pasi	NOUN
dpc-1664	38	35	12	12	NUM
dpc-1664	38	36	to	to	PART
dpc-1664	38	37	pasi	pasi	VERB
dpc-1664	38	38	20	20	NUM
dpc-1664	38	39	(	(	PUNCT
dpc-1664	38	40	figure	figure	NOUN
dpc-1664	38	41	1b	1b	NUM
dpc-1664	38	42	)	)	PUNCT
dpc-1664	38	43	.	.	PUNCT
dpc-1664	39	1	the	the	DET
dpc-1664	39	2	patient	patient	NOUN
dpc-1664	39	3	was	be	AUX
dpc-1664	39	4	followed	follow	VERB
dpc-1664	39	5	up	up	ADP
dpc-1664	39	6	to	to	ADP
dpc-1664	39	7	the	the	DET
dpc-1664	39	8	next	next	ADJ
dpc-1664	39	9	visit	visit	NOUN
dpc-1664	39	10	,	,	PUNCT
dpc-1664	39	11	and	and	CCONJ
dpc-1664	39	12	after	after	ADP
dpc-1664	39	13	12	12	NUM
dpc-1664	39	14	weeks	week	NOUN
dpc-1664	39	15	of	of	ADP
dpc-1664	39	16	treatment	treatment	NOUN
dpc-1664	39	17	,	,	PUNCT
dpc-1664	39	18	there	there	PRON
dpc-1664	39	19	was	be	VERB
dpc-1664	39	20	a	a	DET
dpc-1664	39	21	reduction	reduction	NOUN
dpc-1664	39	22	of	of	ADP
dpc-1664	39	23	pasi	pasi	NOUN
dpc-1664	39	24	(	(	PUNCT
dpc-1664	39	25	pasi	pasi	NOUN
dpc-1664	39	26	score	score	NOUN
dpc-1664	39	27	5	5	NUM
dpc-1664	39	28	)	)	PUNCT
dpc-1664	39	29	and	and	CCONJ
dpc-1664	39	30	good	good	ADJ
dpc-1664	39	31	clinical	clinical	ADJ
dpc-1664	39	32	improvement	improvement	NOUN
dpc-1664	39	33	,	,	PUNCT
dpc-1664	39	34	with	with	ADP
dpc-1664	39	35	complete	complete	ADJ
dpc-1664	39	36	resolution	resolution	NOUN
dpc-1664	39	37	of	of	ADP
dpc-1664	39	38	plaque	plaque	NOUN
dpc-1664	39	39	psoriasis	psoriasis	NOUN
dpc-1664	39	40	and	and	CCONJ
dpc-1664	39	41	guttate	guttate	ADJ
dpc-1664	39	42	lesions	lesion	NOUN
dpc-1664	39	43	after	after	ADP
dpc-1664	39	44	16	16	NUM
dpc-1664	39	45	weeks	week	NOUN
dpc-1664	39	46	of	of	ADP
dpc-1664	39	47	treatment	treatment	NOUN
dpc-1664	39	48	(	(	PUNCT
dpc-1664	39	49	pasi	pasi	NOUN
dpc-1664	39	50	 	 	SPACE
dpc-1664	39	51	0	0	NUM
dpc-1664	39	52	)	)	PUNCT
dpc-1664	39	53	(	(	PUNCT
dpc-1664	39	54	figure	figure	NOUN
dpc-1664	39	55	1c	1c	NOUN
dpc-1664	39	56	)	)	PUNCT
dpc-1664	39	57	.	.	PUNCT
dpc-1664	40	1	complete	complete	ADJ
dpc-1664	40	2	resolution	resolution	NOUN
dpc-1664	40	3	of	of	ADP
dpc-1664	40	4	cutaneous	cutaneous	ADJ
dpc-1664	40	5	plaque	plaque	NOUN
dpc-1664	40	6	and	and	CCONJ
dpc-1664	40	7	guttate	guttate	ADJ
dpc-1664	40	8	psoriasis	psoriasis	NOUN
dpc-1664	40	9	was	be	AUX
dpc-1664	40	10	achieved	achieve	VERB
dpc-1664	40	11	after	after	ADP
dpc-1664	40	12	12	12	NUM
dpc-1664	40	13	months	month	NOUN
dpc-1664	40	14	of	of	ADP
dpc-1664	40	15	treatment	treatment	NOUN
dpc-1664	40	16	(	(	PUNCT
dpc-1664	40	17	figure	figure	NOUN
dpc-1664	40	18	1d	1d	NUM
dpc-1664	40	19	)	)	PUNCT
dpc-1664	40	20	.	.	PUNCT
dpc-1664	41	1	conclusions	conclusion	NOUN
dpc-1664	41	2	psoriasis	psoriasis	NOUN
dpc-1664	41	3	is	be	AUX
dpc-1664	41	4	a	a	DET
dpc-1664	41	5	complex	complex	ADJ
dpc-1664	41	6	disease	disease	NOUN
dpc-1664	41	7	,	,	PUNCT
dpc-1664	41	8	caused	cause	VERB
dpc-1664	41	9	by	by	ADP
dpc-1664	41	10	an	an	DET
dpc-1664	41	11	inflammatory	inflammatory	ADJ
dpc-1664	41	12	cascade	cascade	NOUN
dpc-1664	41	13	involving	involve	VERB
dpc-1664	41	14	cytokines	cytokine	NOUN
dpc-1664	41	15	as	as	ADP
dpc-1664	41	16	tnfα	tnfα	NOUN
dpc-1664	41	17	,	,	PUNCT
dpc-1664	41	18	and	and	CCONJ
dpc-1664	41	19	the	the	DET
dpc-1664	41	20	il-17	il-17	NOUN
dpc-1664	41	21	/	/	SYM
dpc-1664	41	22	il-23	il-23	NOUN
dpc-1664	41	23	axis	axis	NOUN
dpc-1664	41	24	.	.	PUNCT
dpc-1664	42	1	there	there	PRON
dpc-1664	42	2	are	be	VERB
dpc-1664	42	3	currently	currently	ADV
dpc-1664	42	4	different	different	ADJ
dpc-1664	42	5	treatment	treatment	NOUN
dpc-1664	42	6	options	option	NOUN
dpc-1664	42	7	to	to	PART
dpc-1664	42	8	control	control	VERB
dpc-1664	42	9	the	the	DET
dpc-1664	42	10	disease	disease	NOUN
dpc-1664	42	11	.	.	PUNCT
dpc-1664	43	1	according	accord	VERB
dpc-1664	43	2	to	to	ADP
dpc-1664	43	3	new	new	ADJ
dpc-1664	43	4	evidence	evidence	NOUN
dpc-1664	43	5	,	,	PUNCT
dpc-1664	43	6	it	it	PRON
dpc-1664	43	7	is	be	AUX
dpc-1664	43	8	important	important	ADJ
dpc-1664	43	9	to	to	PART
dpc-1664	43	10	build	build	VERB
dpc-1664	43	11	personalized	personalized	ADJ
dpc-1664	43	12	therapy	therapy	NOUN
dpc-1664	43	13	considering	consider	VERB
dpc-1664	43	14	the	the	DET
dpc-1664	43	15	characteristics	characteristic	NOUN
dpc-1664	43	16	of	of	ADP
dpc-1664	43	17	psoriasis	psoriasis	NOUN
dpc-1664	43	18	and	and	CCONJ
dpc-1664	43	19	the	the	DET
dpc-1664	43	20	presence	presence	NOUN
dpc-1664	43	21	of	of	ADP
dpc-1664	43	22	co	co	NOUN
dpc-1664	43	23	-	-	NOUN
dpc-1664	43	24	morbidities	morbidity	NOUN
dpc-1664	43	25	that	that	PRON
dpc-1664	43	26	may	may	AUX
dpc-1664	43	27	affect	affect	VERB
dpc-1664	43	28	the	the	DET
dpc-1664	43	29	clinical	clinical	ADJ
dpc-1664	43	30	response	response	NOUN
dpc-1664	43	31	.	.	PUNCT
dpc-1664	44	1	here	here	ADV
dpc-1664	44	2	we	we	PRON
dpc-1664	44	3	reported	report	VERB
dpc-1664	44	4	the	the	DET
dpc-1664	44	5	effectiveness	effectiveness	NOUN
dpc-1664	44	6	of	of	ADP
dpc-1664	44	7	risankizumab	risankizumab	NOUN
dpc-1664	44	8	for	for	ADP
dpc-1664	44	9	both	both	CCONJ
dpc-1664	44	10	psoriatic	psoriatic	ADJ
dpc-1664	44	11	plaque	plaque	NOUN
dpc-1664	44	12	and	and	CCONJ
dpc-1664	44	13	guttate	guttate	NOUN
dpc-1664	44	14	psoriasis	psoriasis	NOUN
dpc-1664	44	15	.	.	PUNCT
dpc-1664	45	1	references	reference	NOUN
dpc-1664	45	2	1	1	NUM
dpc-1664	45	3	.	.	X
dpc-1664	45	4	fang	fang	PROPN
dpc-1664	45	5	r	r	PROPN
dpc-1664	45	6	,	,	PUNCT
dpc-1664	45	7	sun	sun	NOUN
dpc-1664	45	8	q.	q.	PROPN
dpc-1664	45	9	guttate	guttate	PROPN
dpc-1664	45	10	psoriasis	psoriasis	NOUN
dpc-1664	45	11	.	.	PUNCT
dpc-1664	46	1	indian	indian	ADJ
dpc-1664	46	2	pediatr	pediatr	NOUN
dpc-1664	46	3	.	.	PUNCT
dpc-1664	47	1	2020;57(6):596597	2020;57(6):596597	NUM
dpc-1664	47	2	.	.	PUNCT
dpc-1664	48	1	doi	doi	NOUN
dpc-1664	48	2	:	:	PUNCT
dpc-1664	48	3	10.1007	10.1007	NUM
dpc-1664	48	4	/	/	SYM
dpc-1664	48	5	s13312	s13312	VERB
dpc-1664	48	6	-	-	PUNCT
dpc-1664	48	7	020	020	NUM
dpc-1664	48	8	-	-	PUNCT
dpc-1664	48	9	1880	1880	NUM
dpc-1664	48	10	-	-	SYM
dpc-1664	48	11	0	0	NUM
dpc-1664	48	12	.	.	PUNCT
dpc-1664	49	1	pmid	pmid	NOUN
dpc-1664	49	2	:	:	PUNCT
dpc-1664	49	3	32562412	32562412	NUM
dpc-1664	49	4	.	.	PUNCT
dpc-1664	50	1	2	2	X
dpc-1664	50	2	.	.	X
dpc-1664	50	3	shalanda	shalanda	PROPN
dpc-1664	50	4	l.	l.	PROPN
dpc-1664	50	5	hall	hall	PROPN
dpc-1664	50	6	,	,	PUNCT
dpc-1664	50	7	 	 	SPACE
dpc-1664	50	8	wasim	wasim	PROPN
dpc-1664	50	9	haidari	haidari	PROPN
dpc-1664	50	10	,	,	PUNCT
dpc-1664	50	11	 	 	SPACE
dpc-1664	50	12	steven	steven	PROPN
dpc-1664	50	13	r.	r.	PROPN
dpc-1664	50	14	feldman	feldman	PROPN
dpc-1664	50	15	.	.	PUNCT
dpc-1664	51	1	resolution	resolution	NOUN
dpc-1664	51	2	of	of	ADP
dpc-1664	51	3	guttate	guttate	ADJ
dpc-1664	51	4	psoriasis	psoriasis	NOUN
dpc-1664	51	5	plaques	plaque	NOUN
dpc-1664	51	6	after	after	ADP
dpc-1664	51	7	one	one	NUM
dpc-1664	51	8	-	-	PUNCT
dpc-1664	51	9	time	time	NOUN
dpc-1664	51	10	administration	administration	NOUN
dpc-1664	51	11	of	of	ADP
dpc-1664	51	12	guselkumab	guselkumab	NOUN
dpc-1664	51	13	.	.	PUNCT
dpc-1664	52	1	j	j	PROPN
dpc-1664	52	2	drugs	drug	NOUN
dpc-1664	52	3	dermatol	dermatol	NOUN
dpc-1664	52	4	.	.	PUNCT
dpc-1664	53	1	2019;18(8):822	2019;18(8):822	NOUN
dpc-1664	53	2	-	-	SYM
dpc-1664	53	3	823	823	NUM
dpc-1664	53	4	.	.	PUNCT
dpc-1664	54	1	3	3	X
dpc-1664	54	2	.	.	X
dpc-1664	54	3	dattola	dattola	PROPN
dpc-1664	54	4	a	a	PRON
dpc-1664	54	5	,	,	PUNCT
dpc-1664	54	6	silvestri	silvestri	PROPN
dpc-1664	54	7	m	m	PROPN
dpc-1664	54	8	,	,	PUNCT
dpc-1664	54	9	tamburi	tamburi	PROPN
dpc-1664	54	10	f	f	PROPN
dpc-1664	54	11	,	,	PUNCT
dpc-1664	54	12	amoruso	amoruso	PROPN
dpc-1664	54	13	gf	gf	PROPN
dpc-1664	54	14	,	,	PUNCT
dpc-1664	54	15	bennardo	bennardo	PROPN
dpc-1664	54	16	l	l	NOUN
dpc-1664	54	17	,	,	PUNCT
dpc-1664	54	18	nisticò	nisticò	PROPN
dpc-1664	54	19	sp	sp	PROPN
dpc-1664	54	20	.	.	PUNCT
dpc-1664	54	21	emerging	emerge	VERB
dpc-1664	54	22	role	role	NOUN
dpc-1664	54	23	of	of	ADP
dpc-1664	54	24	anti	anti	ADJ
dpc-1664	54	25	-	-	ADJ
dpc-1664	54	26	il23	il23	PROPN
dpc-1664	54	27	in	in	ADP
dpc-1664	54	28	the	the	DET
dpc-1664	54	29	treatment	treatment	NOUN
dpc-1664	54	30	of	of	ADP
dpc-1664	54	31	psoriasis	psoriasis	NOUN
dpc-1664	54	32	:	:	PUNCT
dpc-1664	54	33	when	when	SCONJ
dpc-1664	54	34	humanized	humanize	VERB
dpc-1664	54	35	is	be	AUX
dpc-1664	54	36	very	very	ADV
dpc-1664	54	37	promising	promising	ADJ
dpc-1664	54	38	.	.	PUNCT
dpc-1664	55	1	dermatol	dermatol	NOUN
dpc-1664	55	2	ther	ther	ADV
dpc-1664	55	3	.	.	PUNCT
dpc-1664	56	1	2020	2020	NUM
dpc-1664	56	2	:	:	PUNCT
dpc-1664	57	1	e14504	e14504	VERB
dpc-1664	57	2	.	.	PUNCT
dpc-1664	57	3	doi	doi	NOUN
dpc-1664	57	4	:	:	PUNCT
dpc-1664	57	5	10.1111	10.1111	NUM
dpc-1664	57	6	/	/	SYM
dpc-1664	57	7	dth.14504	dth.14504	PROPN
dpc-1664	57	8	.	.	PUNCT
dpc-1664	58	1	figure	figure	NOUN
dpc-1664	58	2	1	1	NUM
dpc-1664	58	3	.	.	PUNCT
dpc-1664	59	1	(	(	PUNCT
dpc-1664	59	2	a	a	X
dpc-1664	59	3	)	)	PUNCT
dpc-1664	59	4	start	start	NOUN
dpc-1664	59	5	of	of	ADP
dpc-1664	59	6	risankizumab	risankizumab	NOUN
dpc-1664	59	7	treatment	treatment	NOUN
dpc-1664	59	8	.	.	PUNCT
dpc-1664	60	1	(	(	PUNCT
dpc-1664	60	2	b	b	X
dpc-1664	60	3	)	)	PUNCT
dpc-1664	60	4	clinical	clinical	ADJ
dpc-1664	60	5	situation	situation	NOUN
dpc-1664	60	6	after	after	ADP
dpc-1664	60	7	1	1	NUM
dpc-1664	60	8	month	month	NOUN
dpc-1664	60	9	of	of	ADP
dpc-1664	60	10	treatment	treatment	NOUN
dpc-1664	60	11	following	follow	VERB
dpc-1664	60	12	an	an	DET
dpc-1664	60	13	episode	episode	NOUN
dpc-1664	60	14	of	of	ADP
dpc-1664	60	15	sore	sore	ADJ
dpc-1664	60	16	throat	throat	NOUN
dpc-1664	60	17	with	with	ADP
dpc-1664	60	18	positive	positive	ADJ
dpc-1664	60	19	streptozyme	streptozyme	NOUN
dpc-1664	60	20	test	test	NOUN
dpc-1664	60	21	.	.	PUNCT
dpc-1664	61	1	(	(	PUNCT
dpc-1664	61	2	c	c	X
dpc-1664	61	3	)	)	PUNCT
dpc-1664	61	4	complete	complete	ADJ
dpc-1664	61	5	resolution	resolution	NOUN
dpc-1664	61	6	of	of	ADP
dpc-1664	61	7	plaque	plaque	NOUN
dpc-1664	61	8	psoriasis	psoriasis	NOUN
dpc-1664	61	9	and	and	CCONJ
dpc-1664	61	10	guttate	guttate	ADJ
dpc-1664	61	11	lesions	lesion	NOUN
dpc-1664	61	12	after	after	ADP
dpc-1664	61	13	16	16	NUM
dpc-1664	61	14	weeks	week	NOUN
dpc-1664	61	15	of	of	ADP
dpc-1664	61	16	treatment	treatment	NOUN
dpc-1664	61	17	.	.	PUNCT